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1 INTRODUCTION 
 
 
Molecular imaging is an emerging discipline in the field of biomedical research. 
Though already used routinely in diagnostics at clinical radiology departments; 
molecular imaging methods offer innovative non-invasive means, which in addition to 
diagnostics can be used to characterize and quantify biological processes at a cellular 
and subcellular level (Massoud & Gambhir 2003). In an experimental research setting 
this enables the longitudinal observation of intact living subjects with sufficient spatial 
and temporal resolution. Furthermore, the advances in multimodality imaging have 
introduced new methods to better understand biological responses through the use of 
molecular probes in addition to intrinsic sources of image contrast i.e. tissue (Willman 
et al 2008). A clear advantage over in vitro methods (e.g. cell cultures) is the use of 
intact living subjects. Furthermore, through the development of more sensitive devices, 
the use of small animals, such as mice or rats in addition to large animals, enable 
molecular imaging methods to be used in preclinical studies as well as in clinical 
studies. 
 
Cellulose nanofibrils are nanometer range materials that are showing potential uses in 
many different fields of science, e.g. biomaterial studies (Klemm et al. 2011). The 
nature-based nanofibrillar cellulose (NFC) is from a sustainable source with unique 
characteristics. The nanoscale structure and dimensions enable many useful functions, 
which also however, present risks as the interaction properties become more dominant. 
In the literature review part, the main focus will be on the medical and life-science 
applications. 
 
As a potential biomaterial, bacterial nanofibrillar cellulose (BNC) has already been 
studied extensively (Klemm et al. 2011). In addition, the properties of the material itself 
have been well characterized. However, the use of plant-derived NFC as a potential 
biomedical device has only been recently investigated (Borges et al. 2011; Mathew et 
al. 2012). Despite the similarities of the two materials, there are a few advantages and 
disadvantages with the use of wood pulp cellulose nanofibers. Mainly as the source of 
the material is nigh inexhaustible, it is easily sustainable for industrial scale production, 
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therefore being very cost efficient. However it has been shown that the shape and 
structure of bacterial nanofibrillar cellulose is more easily controlled, in addition to 
being more pure than the plant-derived NFC (Klemm et al. 2011). Therefore it is clear 
that the biocompatibility and other biomedical application research have been focusing 
more in the bacteria-synthesized material. 
 
To evaluate the functionality of the nanofibrillar cellulose in in vivo conditions, the 
experimental part of this master’s thesis focuses on a minimal invasive study of a plant-
derived NFC to be used as a novel application, drug releasing hydrogel “implant”. The 
release and distribution of three different compounds were investigated with a single-
photon emission computed tomography and x-ray computed tomography multimodality 
device (SPECT/CT). 
 
The other aspect of this master’s thesis is to evaluate the plant-derived nanofibrillar 
implant as a potential biomedical device through the means of molecular imaging. 
Therefore the literature review part focuses mainly on SPECT/CT imaging and NFC, its 
characteristics in addition to current research and potential applications. 
 
 
2 CELLULOSE NANOFIBERS 
 
2.1 Properties 
 
Cellulose is the most abundant naturally occurring biopolymer of glucose and it has 
been used for over 150 years as a chemical raw material in several fields of industry 
(Klemm et al. 2011). The structural features and reactivity has led to a creation of novel 
materials as well as advancements in composite materials, reinforcing existing 
properties (Pääkkö et al 2007). Currently applications for novel forms of celluloses are 
under investigation, namely the development of, and applications for nanoscale 
celluloses (Klemm et al. 2011). 
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The characterization and properties of nanoscale celluloses largely depends on the 
production method (Klemm et al. 2011). Top-down methods involve enzymatic, 
chemical and physical methodologies to isolate and separate individual microfibrils 
from plant cellulose, i.e. wood pulp (Fig 1). Microfibrils are bundles of cellulose 
macromolecule chains ranging from 5 to 60 nm in diameter and several micrometers in 
length. Another top-down method uses acid hydrolysis treatment to remove the 
amorphous sections from the microfibrils yielding in highly crystalline nanoscale 
cellulose rods or whiskers of 5-70 nm in diameter and 100-250 nm in length. Finally a 
biotechnological assembly method for nanofiber cellulose network synthesis is 
fermentation with sugars and plant carbohydrates in some bacteria (Klemm et al. 2011). 
The excreted film or gel is a stable and tight nanofiber network of fibrils 20 to 100 nm 
in diameter. However cellulose nanofibers synthesized by fermentation are pure (free of 
hemicelluloses), in addition, the plant derived products might have a small amount of 
biogenic residues such as lignin and pectin, thus requiring an additional purification 
protocol. 
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Figure 1. Schematics showing the release of cellulose nanofibrils from the natural fibers 
by different conversion methods. Different technologies yield in different products. 
Image taken from the Finnish Centre of Nanocellulosic technologies (VTT, Helsinki 
University of Technology, UPM). 
 
 
The cellulose microfibril (or nanofiber depending on the nomenclature) aqueous 
suspensions behave as gels with pseudoplastic and thixotropic properties (Pääkkö et al 
2007; Klemm et al. 2011). They are characterized by high water retention capabilities 
(i.e. gels are formed at very low concentrations), hydrophilicity and semicrystalline 
fiber morphology. Single fibrils have a very high stiffness rating (Young’s modulus of 
134 GPa) and tensile strength (2 GPa), with a small thermal expansion coefficient 
similar to glass (Klemm et al. 2006). In neutral pH, NFC is slightly negative in charge, 
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and the charge weakens as the surrounding pH is lowered (Kolakovic et al. 2012 B) In 
addition cellulose nanofibers have inherent versatile chemical modification properties 
(Eichhorn et al. 2001), which are important in producing additives and composites. 
 
Cellulose microfibril dispersion storage modulus (the materials ability to store energy) 
and loss modulus (the materials ability to dissipate energy) are independent of angular 
frequency, in addition the storage modulus being high compared to loss modulus 
(Pääkkö et al. 2007), as it is with ideal gels. In contrast, classical viscous fluids storage 
and loss modulus are frequency dependent and the loss modulus is considerably lower 
than storage modulus (Klemm et al. 2011). 
 
The storage modulus of microfibrillar cellulose is also highly dependent on the 
concentration and has a shear-thinning effect (Pääkkö et al. 2007), which is important in 
several industrial applications such as processing and coating (Klemm et al. 2011) The 
high modulus is due to the high strength of nanofibrillar network (Pääkkö et al. 2007). 
In addition highly controllable viscosity makes it versatile in its possible applications, as 
the modulus can be tuned 5 orders of magnitude by changing the concentration (Pääkkö 
et al. 2007). However shear-thinning has other benefits, for example in medicinal field 
or biomaterial research as it makes material handling much easier while retaining its 
desired viscosity in the application. 
 
For further properties of NFC, there have been many studies investigating preparation 
methods, source materials and nanocomposite potential. In the review by Siró and 
Plackett (2010) these properties have been discussed in great detail. 
 
2.2 Biomaterial research 
 
Biomaterials are designed and constructed to interact with biological material, such as 
cells and tissue. Therefore they must be non-toxic, biocompatible, provide sufficient 
structural strength and properties as well as depending on the application either be 
biodegradable or non-biodegradable. Currently there are four different main categories 
of biomaterials: metals, ceramics, polymers and composites, each with their strengths 
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and limitations. However, nanoparticles and nanomaterials have unique 
physicochemical properties, which might cause an unexpected disruption of normal 
function in biological structures, as it is known that nanoparticles promote several 
different diseases and disabilities (Buzea et al. 2008). 
 
Concern of cellulose nanofiber safety is related to its properties, such as needle like 
shape (rods, whiskers) and its persistence in body (i.e. non-biodegradable). However 
cellulose nanofiber structure is flexible unlike in inorganic fibres, which might alleviate 
the possible adverse effects from the needle like shape. 
 
Studies of cellulose tissue biocompatibility have been made to investigate cellulose 
toxicity. The in vivo absorbance by living tissue seems to be dependent on the degree of 
crystallinity and the chemical structure; however reaction to foreign material in body 
was found relatively mild suggesting that cellulose is indeed biocompatible (Miyamoto 
et al. 1989). In another histological study on rats, a moderate foreign body tissue 
reaction was found (Märtson et al. 1999). However, 60 weeks after implantation, tissue 
recovery was observed and reaction to foreign material became milder. The 
subcutaneous implant did not degrade during the study period which indicates high 
biodurability. 
 
Several studies afterwards have shown the safety of nanofibrillar cellulose. It was 
reported that no morphological changes were found, in addition to the absence of 
mRNA inhibition in vitro (Pitkänen et al. 2010). Nanofibrillar cellulose did not affect 
cellular growth or promote mutagenicity. Furthermore it has been shown that 
nanocrystalline cellulose does not cause genotoxicity (Vartiainen et al. 2011). 
Inflammatory effects and cytotoxicity have also been reported to be negative. 
 
In biomaterial research it is important that the material acts as a template for a 
biomimetic purpose. Therefore it has to be biologically inert, i.e. non-toxic and 
biocompatible while still providing the desired functions for the application. 
Considering aforementioned nanofibrillar cellulose properties, NFC biomaterial could 
show usefulness as a connective tissue, replacement skin, bone composite or cartilage 
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material. In addition with the positive biocompatibility studies, nanofibrillar cellulose is 
a very promising material in the biomaterial research. However implant migration and 
non-biodegradability in living tissue might still be an issue in the future if not properly 
investigated. 
 
2.3 Applications 
 
Currently nanofibrillar cellulose is the subject of intensive research and development 
(Klemm et al. 2005). In addition, cellulose is a self-renewable raw material which 
makes it interesting for large industries as well. Cellulose biopolymers offer specific 
properties different from other natural and synthetic polymers, such as hydrophilicity, 
chirality, broad chemical modification capacity, semicrystalline morphologies and 
biodegradability depending on the application. These unique characteristics emphasize 
the bacterial and wood celluloses enormous potential in several applications on different 
fields of science.  
 
The nanosized architecture and versatility of cellulose has tailored innovative products 
for science, medicine, food industry, paper industry and cosmetics (Klemm et al. 2006). 
Various types of celluloses are the design of controllable supramolecular structure in the 
production stage. The dominant source of cellulose is from plants, for example cotton in 
which cellulose is in near pure state. In addition non-pathogenic cellulose forming 
bacteria, namely Acetobacter strains, are suitable for cellulose production. 
 
In nanoscale, nanofibrillar cellulose shows nanoporosity and transparency in dispersions 
and composite materials (Klemm et al. 2009). This is important in the fabrication of 
nanoporous membranes and scaffolds, for example in hard and soft tissue repair; 
basically mimicking a living system. In addition the chemical modification processes 
can be utilized through the carbohydrate-binding modules (CBM’s; former cellulose-
binding domain CBD; Gilkes et al. 1991). CBM’s allow further modification of 
celluloses, for example in the formation of composites to strengthen material properties 
including biomimetic characteristics (Laaksonen et al. 2011). Additional ways of 
modification have been found through xylans (Linder & Gatenholm 2004), and utilized 
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in enhanced adhesion and proliferation of endothelial cells onto bacterial cellulose 
(Bodin et al. 2007). 
 
The sustainability and vast sources of cellulose offer near unlimited and cost efficient 
raw materials for industry and science. Considering the biocompatibility and versatility, 
celluloses offer many new aspects in the development and design of several different 
and interesting applications in material sciences. 
 
2.3.1 Bacterial cellulose 
 
Bacterial cellulose has specific characteristics over nanofibrillar cellulose derived from 
wood pulp, which yields some unique properties mainly due to the biotechnological 
production technique (Klemm et al. 2005). Bacterial cellulose is a product of bottom-up 
method contrary to the plant derived top-down processing. Therefore bacterial cellulose 
offers different characteristics, such as the control of supramolecular structure and 
properties during cultivation, shaping of the material during biosynthesis, direct 
cellulose coating by thin layer cultivation, in situ composite formation, cellulose 
specificity, effective post process modification and very high purity (Klemm et al. 
2009). Efficient ways to control the biosynthesis process (thickness, consistency, fibre 
network structure) include the choice of the bacterial strain in addition to the cultivation 
conditions, for example additional chemical additives. The shape can be controlled by 
different moulds and sintering techniques, most importantly the in situ production 
methods. This allows the formation of precise structures required for example in tissue 
grafts. 
 
First applications of bacterial celluloses in the medical field were their use as wound 
dressings (Klemm et al. 2009). However in chronic wound healing bacterial cellulose 
has not shown significant effect as the persistent inflammation prevents normal wound 
healing processes (Wiegand et al. 2006). Therefore composite materials have been 
investigated and proposed regarding this issue, and the incorporation of collagen type I 
into the bacterial cellulose has shown to reduce degrading enzymes and pro-
inflammatory interleukins (Wiegand et al. 2006). In addition, the properties of bacterial 
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cellulose have been assessed as a potential wet wound dressing application (Clasen et 
al. 2006) as it provides a moist environment resulting in better wound healing. 
 
Another important factor in wound healing is to prevent microbial contamination. An 
antimicrobial effect has been achieved by impregnating and fixing silver nanoparticles 
inside the bacterial cellulose fibre network (Maneerung et al. 2007). Strong 
antimicrobial effect was shown against Escherichia coli and Staphylococcus aureus. 
 
Furthermore, pellicular hydrogel like liquid films have been proposed for wound 
dressings and burn-healing (Jung & Jin 2007). In this study, another natural polymer 
formed by silk fibroin was introduced into bacterial cellulose to form a strong and 
flexible composite film in its wet state; a potential novel wound healing biomaterial. 
 
However, other medical devices has been designed and proposed in addition to wound 
dressings. In biomaterials research nanofibrillar cellulose has been investigated as a 
possible use in orthopaedics (Hutchens et al 2006). In this study bacterial cellulose was 
combined with hydroxyapatite as a template graft for osseous defects. The biomaterial 
promoted bone colonization and degraded over time in replacement of new bone tissue. 
In addition, bacterial cellulose microvessels have been investigated for microsurgical 
implants, as in cardiovascular grafts (Schumann et al. 2009). Bacterial cellulose 
microvessels were implanted into defect carotid arteries in rats and pigs. The two 
studies show the bacterial cellulose vessel to be a potent, biocompatible and stable 
vascular conduit, which suggest it could be an approachable aspect in part of 
cardiovascular tissue-engineering programs. Additional in vitro studies on stress-strain 
responses of the carotid artery for tissue engineered bacterial cellulose blood vessels 
have been performed, showing similar properties than the porcine carotid artery 
(Bäckdahl et al. 2006). 
 
Current research in bacterial cellulose consists of two main categories: wound dressings 
and novel active implants (Klemm et al. 2011). However, new designs have been 
proposed, such as bacterial cellulose scaffolds in cornea tissue engineering (Hui et al. 
2009), and LiCl-impregnated bacterial cellulose, which shows bending actuation 
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properties in its hydrated state (Jeon et al. 2010). A possible application for a smart 
material where applying mechanical force will result in proportional ionic conductivity. 
Highly actuating and biocompatible material in a wet environment could be an 
interesting combination of properties in both sensor technologies and biomedical 
devices. Furthermore it has been shown that bacterial cellulose porosity can be 
controlled through density with different material handling processes (Hu & Catchmark, 
2009), which is required in tissue engineering when an essential nanostructure is 
desired. In addition, a delivery method for targeted drug-delivery has been proposed 
with the use of ferromagnetism (Vitta & Thiruvengadam, 2012), which could be a 
potential application for targeted delivery of anticancer drugs. 
 
2.3.2 Plant-derived cellulose 
 
Plant-derived cellulose, or micro-/nanofibrillar cellulose, is obtained from wood pulp by 
applying mechanical pressure and grinding forces with chemical and/or enzymatic pre-
treatment (Klemm et al. 2011). Proper delaminating processes require multiple passes 
through the homogenizers until a gel-like nanofibrillar ultra-structure is achieved. The 
energy consumption of the homogenization has been the main impediment of 
commercial production of nanofibrillar cellulose. However, after the discovery of using 
primary wall cellulose as opposed to secondary wall materials (Dinand et al. 1996), the 
production of nanofibrillar cellulose became more viable. 
 
Plant-derived cellulose has been mainly used in technical applications (Klemm et al. 
2011). Therefore wood pulp cellulose has already achieved great interest mostly in 
paper technologies and sciences (Ahola et al. 2008; Henriksson et al. 2008) as well as 
analytical purposes (Bonné et al. 2010). However, some studies have shown the 
potential benefit of plant-derived celluloses as biomedical applications and devices.  
 
Native NFC hydrogels were studied and investigated as potential 3D cell culture 
scaffolds (Bhattacharya et al. 2012). The scaffolds were shown to provide feasible and 
biocompatible microenvironments for cell studies where the absence of other animal or 
human derived components is desirable. In addition, NFC hydrogel composites have 
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been investigated as potential replacements of the nucleus pulposus in regenerative 
medicine (Borges et al. 2011; Eyholzer et al 2011). The prepared hydrogels expressed 
biocompatibility with cartilage fetal cells (Eyholzer et al. 2011) and similar 
characteristics when compared with human nucleus pulposus, such as swelling ratios, 
compression moduli and viscoelastic behaviour (Borges et al. 2011). However, some 
differences were observed in the mechanical properties between the NFC hydrogel 
composites and the human nucleus pulposus. 
 
NFC-polyurethane heart valves and vascular grafts have been shown to express good 
biological durability and haemodynamics (Cherian et al. 2011). In addition, good 
resistance against fatigue was observed in accelerated fatigue tests, where five out of 
five of the prepared heart valves exceeded the equivalent stress of 12 years cycle 
without failure. In addition to NFC-polyurethane grafts, collagen-NFC based 
implantable scaffolds have also shown to provide better mechanical strength and while 
retaining good biocompatibility (Mathew et al 2012 A). However, further optimization 
is required for a specific application; in addition to alternatives for problematic 
crosslinking agents which express cytotoxicity. Therefore, new compositions were 
grafted, referred to as “NF90” and “NF120” (Mathew et al 2012 B). Better 
cytocompatibility was achieved as well as a range of mechanical properties suitable for 
a potential artificial ligament or tendon application. 
 
Plant-derived NFC has been studied as an enhanced stability and drug release matrix 
(Valo et al 2011; Kolakovic et al 2012 A; Kolakovic et al 2012 B). By limiting the rate 
of the drug release, a long-term sustained release application with good mechanical 
properties could be obtained. A steady sustained release was reported for up to 90 days 
in addition to almost zero-order release kinetics for two of the tree study compounds 
(Kolakovic et al 2012 B). For a system that requires a long-term sustained release, 
parenteral, topical and/or ocular deliveries were suggested as potential applications. 
 
Furthermore, an oral application for controlling the postprandial concentrations of blood 
glucose, plasma insulin, glucose-dependent insulinotropic polypeptide and triglyceride 
was investigated (Shimotoyodome et al 2011). Therefore the administered TEMPO-
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oxidized cellulose nanofibers were found to have potential in biomedical applications, 
such as to alleviate symptoms in the long-term complications related to patients with 
diabetes. 
 
Generally it can be concluded that plant-derived NFC has potential use as an application 
in cell therapy and tissue engineering in addition to drug and chemical testing. These 
recent studies will most likely increase the attention towards wood pulp NFC in the 
biomedical field, in addition to the predominant bacterial NFC. 
 
2.4 Future perspectives 
 
The number of patents versus applications ratio for nanofibrillar cellulose is very high 
(Klemm et al. 2011), which indicates that the use of nanofibrillar cellulose as a new 
potential nanosized material is just in the beginning. The inherent colloidal and 
rheological properties along with the utility that comes with the high modification 
capacity will increase the interests in nanosciences towards NFC. The basic knowledge 
about the properties and safety of NFC has already been established; in addition the 
usefulness of BNC as a hydrogel has been demonstrated in numerous potential 
biomedical applications. 
 
However the variety of possible applications of NFC is one of its greatest strengths. 
Mainly due to the modification properties and versatility as a composite material, many 
technical applications have been shown to improve existing technologies. In conclusion, 
the use of NFC as a renewable and cost efficient raw material in the constantly 
developing field of nanosciences will be a great asset to industry as well as towards 
nanotechnologies used in biomedical and other scientific fields in large variety. NFC is 
a valuable asset in the future especially as a nanoscale reinforcement material for further 
technological advancements, which will lead to a better quality of life of man as well as 
lessen the ecological burden by being environmentally safe and biodegradable. Simple 
and cost efficient production methods from an abundant and renewable source will also 
lower the economical hurdles of many costly industrial scale projects. The increasing 
attention will yield even more novel applications of NFC in the near future. 
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3 SPECT/CT 
 
3.1 Single-photon emission computed tomography 
 
Single-photon emission computed tomography (SPECT) is an imaging technique used 
in nuclear medicine. The working principle is similar to a conventional planar gamma 
camera; however the data acquired with SPECT can be processed into 3D images that 
are independent of patient position and orientation (Hirschmann et al. 2012). The 3D 
image datasets are constructed by a computer applying tomographic reconstruction 
algorithms to multiple projections taken from different angles with a gantry mounted 
rotating gamma camera (Fig 2). To hasten the image acquisition, multiple gamma 
cameras can be used simultaneously. Datasets are typically presented as cross-sectional 
slices through the patient; however these datasets can be freely manipulated as required. 
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Figure 2. A schematic of SPECT acquiring projections during a scan. Detectors are 
mounted on a gantry which rotates around the subject (or patient) and detect the gamma 
energy emitted by radionuclides. Individual projections are reconstructed into 
tomographic slices that can be further reconstructed into 3-dimensional images. The 
reconstruction algorithms require time to process the raw data; therefore the full image 
can be acquired only after the full scan has been performed. 
 
 
 
For its imaging purposes SPECT requires gamma-emitting radioisotopes (or 
radionuclides) that use ionizing radiation as a source of detection. A common detector 
system utilizes thallium-activated sodium iodide crystals (NaI(Tl)) to detect and convert 
the gamma ray energy emitted by the radionuclides (Fig 3). Energy is converted into 
visible scintillation light which is amplified by a set of photomultiplier tubes into 
electrical signals. This signal data can be readily reconstructed into tomographic 
images. Each radionuclide has its specific emission energy (keV); therefore it is 
possible to track multiple different radionuclides per scan if the main emission energies 
do not overlap with each other. In addition, with the current advances in nuclear 
physics, a number of radioisotopes with suitable half-lives can be produced readily with 
radionuclide generators or cyclotrons (i.e. particle accelerators) which can be utilized in 
numerous technologies, such as nuclear medicine. However due to the nature of gamma 
emission, a collimator is required to filter out scattering photons. 
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Figure 3. Gamma rays are detected by an inorganic scintillation crystal and converted 
into scintillation light. The signal is amplified and converted into electrical pulses that 
are recognized by computational softwares. A tomographic reconstruction algorithm 
assembles the projections into images. 
 
 
Collimator is a lead plate with several holes in it. Lead absorbs photons which are not 
on a direct path to the detector (Fig 4). SPECT sensitivity and resolution is therefore 
determined by the number and diameter of the holes, in addition to the collimator 
thickness. Eliminating photons reduces SPECT sensitivity; however the resolution is 
improved yielding in much clearer images. 
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Figure 4. Lead collimators are required to filter out unfocused radiation from the source. 
Unparallel rays are not detected resulting in lower intensity and therefore sensitivity. 
Image resolution, however, will improve depending on the hole size, number of holes 
and collimator thickness. In principle, only the photons that are on a direct path to the 
detector will be detected. 
 
 
Especially in small animal studies, different types of collimators are required to perform 
the image acquisition. Therefore new collimator designs are developed for greater 
sensitivity and image resolution (Rahmim & Zaidi 2008). Novel types of collimators are 
investigated to improve sensitivity without adversely affecting resolution.  
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3.2 Multimodality 
 
In vivo imaging is an essential tool in gathering structural and functional data from a 
living subject non-invasively; however each imaging modality operates within a defined 
parameter space (Hasegawa et al. 1990). The parameter space is characterized by 
different factors such as spatial and temporal resolution, detection sensitivity, 
penetrating power and quantitative accuracy. Some modalities are well suited for certain 
applications while others are poorly suited for other applications; therefore combining 
different modalities into a single instrument can improve the imaging power of an 
application. 
 
SPECT has a relatively low spatial resolution (Jaszczak, 1981), which can be improved 
by combining it with x-ray computed tomography (CT) (Hasegawa, 1990), which has 
an inherent high-contrast resolution. With CT it is possible to provide detailed structural 
information within tissue (especially bone) while the tissue functionality can be 
observed simultaneously with radioactive probes detected by SPECT; therefore 
combining the two aspects of different imaging modalities. 
 
Multimodality enables the examination of function and structure in the same individual 
at the same time. In nuclear medicine this has led to more efforts in integrating other 
modalities into one device (Cherry, 2006). Most common systems have been 
introducing SPECT or positron emission tomography (PET) with CT. Other 
combination possibilities have been suggested and are commercially available, such as 
PET/MRI (Pichler et al. 2006) and SPECT/MRI (Goetz et al. 2008). Magnetic 
resonance imaging (MRI) presents some specific advantages over conventional CT, 
including high soft tissue contrast, absence of ionizing radiation and sensitivity to tissue 
alteration (Marzola et al. 2003). However several technical challenges delay the 
development of MRI multimodality devices (Cherry, 2009). Inherent high-power 
radiofrequency pulses that interfere with the scintillation detectors and electromagnetic 
waves generated by PET and SPECT power supplies and amplifier electronics makes it 
a difficult to combine these modalities. In addition to the moving parts of SPECT and 
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the need for a collimator are likely to create artifacts in the MR images, which further 
lag the development of a SPECT/MRI device. 
 
In nuclear medicine SPECT/CT is now the standard application in cardiology in 
investigating coronary perfusion and myocardial viability, while it also has many 
applications in neurology and oncology (Rahmim & Zaidi, 2008). However some 
published results suggest PET/CT to be viable in certain cases where diaphragmatic 
attenuation is a hindrance factor (Di Carli & Hachamovitch 2006). In addition, due to 
fludeoxyglucose (
18
F), or 
18
F-FDG, PET/CT has been widely accepted in clinical 
facilities for diagnosis and monitoring of cancer. 
 
3.3 Advantages & limitations 
 
Due to the nature of SPECT systems the resolution is limited by technology and with 
the introduction of parallel-hole and multi-pinhole collimators the resolution and 
imaging speed has been greatly improved since the first single-pinhole collimators 
(Beekman & Vastenhouw, 2004). However this simultaneously lowers the sensitivity of 
the device, which can be somewhat overcome by lengthening scanning times. 
Technological limitation is an advantage over PET whereas its spatial resolution is 
always limited by physical factors (Rahmim & Zaidi, 2008). The intrinsic nature of 
positron type decay and PET coincidence detection system limit the theoretical 
achievable resolution at 2-3 mm, whereas 0.35 mm resolution has been achieved with 
current small-animal SPECT (Beekman & van der Have, 2007). 
 
With PET the sensitivity is approximately two to three orders of magnitudes higher than 
with SPECT (Rahmim & Zaidi, 2008), as the coincidence detection system has no need 
for physical collimators. In addition, radionuclides with short half-lives can be injected 
in higher activities as the cumulative radiation dose remains the same as with emitters 
of longer half-lives. Higher activity administrations also improve signal to noise ratio 
and shorten scanning times, which makes it feasible to perform scans at different fields 
of view within reasonable time. However the longer half-life of single photon emitters 
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widens the detection time window allowing longer observation of the radioactive probes 
and therefore biological processes. 
 
Attenuation correction is a challenge with both PET and SPECT (Rahmim & Zaidi, 
2008). Photon attenuation is a property of emitted radiation interaction with materials 
(or tissue) as it passes through. This leads to a loss of detection due to absorption in the 
material or photons scattering out of the field of view. Attenuation increases image 
noise, artifacts and distortion; therefore attenuation correction for larger study subjects 
is required. Therefore patient differences and variety in tissue thickness further 
complicates the correction (Zaidi & Hasegawa, 2003). Mathematical algorithms applied 
in attenuation correction strategies are necessary for both PET and SPECT, with the 
exception of small animal imaging, where attenuation is not as significant due to thin 
tissue. Furthermore the integration of CT can be used to create attenuation maps for 
each individual subject during acquisition (Zaidi & Hasegawa, 2003). The internal 
anatomic structure provided by the X-ray computed tomography can therefore also be 
used for more precise attenuation corrections. 
 
Time-of-flight (ToF) is the difference of arrival times of dual emitting photons; a 
feature that is used in modern PET imaging systems by detecting the times of arrival of 
the two 511 keV photons (Rahmim & Zaidi, 2008). With ToF it is possible to 
significantly improve image contrast versus noise (Karp et al. 2008), which is another 
sensitivity gain improvement. However in contrast to ToF, PET suffers from random 
coincidences, in which two annihilation photons are detected, but not originated from 
the same event (Rahmim & Zaidi, 2008). Random coincidence results in incorrect pair 
assignment and the annihilated photons true pairs remain undetected. Both ToF and the 
random coincidence complication are not present in SPECT. 
 
Differences in single photon emitting radiotracer energies enable the dual-tracing 
approach for SPECT (Stodilka et al. 2006), which is impossible with current PET 
systems. Multiple energy windows can be monitored simultaneously with a single 
acquisition, which reduces acquisition times, image artifacts of a moving subject and 
subject discomfort (Rahmim & Zaidi, 2008). In addition different pharmacological 
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processes can be examined and different biological variables can be observed 
simultaneously e.g. drug pharmacokinetics. However, a crossover of multiple energy 
windows is present depending on the radiotracers used (Rahmim & Zaidi, 2008). The 
radiotracers energy windows might overlap resulting in one radiotracer contaminating 
the others energy window. 
 
With specialized collimators (e.g. parallel and multi-pinhole collimators) it is possible 
to improve SPECT sensitivity without reducing image resolution (Rahmim & Zaidi, 
2008). Therefore in future prospect, the sensitivity issues are lightened with the use of 
longer half-life radioprobes. In conclusion SPECT/CT offers good resolution and depth 
penetration for clinical and especially for pre-clinical imaging. To further improve 
sensitivity, and overall performance of the imaging modality; collimator technology, 
dual-tracing and attenuation correction still offer many challenges in the future. 
Furthermore PET/CT has received wide clinical acceptance due to the higher relative 
cost of SPECT/CT considering low fraction of its clinical indications (Rahmim & Zaidi, 
2008). However pre-clinical use of SPECT/CT is viewed more cost efficient than 
PET/CT (Willmann et al. 2008). In general the imaging modalities are still considered 
more complementary than competitive. 
 
3.4 Single photon-emitting radionuclides 
 
Single-photon emission (or gamma radiation) is a form of electromagnetic radiation 
where the energy is emitted by unstable nuclei. The nucleus is in an unfavourable 
excited state and has to discharge some of its energy until it eventually relaxes to its 
ground state. The discharged energies can be detected by a gamma camera, which 
utilises single-photon emission. These emitters are called radionuclides or radioisotopes 
and when attached to another compound for the purpose of observing biological 
processes; radiopharmaceuticals, radioactive probes or radiotracers. The principle of 
introducing other compounds with radioisotopes was founded by a Hungarian chemist 
Georg von Hevesy in 1912. 
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3.4.1 Technetium-99m 
 
Technetium-99m (
99m
Tc) is a metastable decay product of molybdenum-99. It has a 
relatively short half-life of 6 hours and emits readily detectable 140 keV gamma rays 
and dissolves in water (Alberto et al 1998). 
99m
Tc-labelled compounds are common in 
several medical applications; such as studying thyroid physiology and pathophysiology 
(Andros et al. 1965), childhood brain tumour diagnostics (O'Tuama et al. 1993), 
myocardial perfusion imaging (Wackers et al. 1989) and cardiac blood pool imaging 
(Thrall et al. 1978). 
99m
Tc is ideal for medicinal use as it is relatively safe in terms of 
half-life and radiation energy. However the half-life is long enough, for example, to 
perform clinical and pre-clinical pharmacokinetics studies with drug molecules of 
similar half-lives. There are commercial kits available that provide the labelling 
protocols with several other pharmaceuticals. In addition water solubility enables 
99m
Tc 
to be used intravenously as well. 
 
3.4.2 Iodine-123 
 
Iodine-123 (
123
I) is a product of cyclotron proton irradiation where ultimately xenon-
123 decays into 
123
I (Fusco et al. 1972). 
123
I has a half-life of 13 hours and decays 
mainly by electron capture which emits 159 keV gamma rays or to a lesser degree by 
internal conversion, emitting a low-energy Auger electron at 127 keV (Narra et al. 
1992); therefore 
123
I is not a pure gamma emitter, however the photon yield is high 
enough for the use with imaging systems (Fusco et al. 1972). In medical applications 
123
I has been found useful in thyroid carcinoma diagnostics (Mandel et al. 2001), and as 
a labelled radiotracer in Parkinson’s disease (Booij et al. 1998) and several different 
clinical dementias (Sharp et al. 1986). 
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3.4.3 Other radionuclides 
 
In addition to 
99m
Tc and 
123
I several other radionuclides for SPECT are in medicinal use 
(Table 1). Radionuclides are used in consideration of their properties. However 
numerous studies are ongoing to improve the safety and efficiency of radionuclide use 
in general radiation work as well as current medical applications of SPECT and PET 
imaging (Cuaron et al. 2011). 
  
 
Table 1. Common radionuclides used in SPECT medicinal imaging. 
 
 
3.5 Radiation safety 
 
Ionizing radiation is not detectable by human senses; therefore the awareness of the 
dangers of radiation must arise from other sources, i.e. understanding the risks related to 
radiation work and knowing ways to protect oneself when handling radioactive material 
is important. In addition to this knowledge, recognizing any potential hazards and acting 
appropriately is the key principle in all radiation practices. 
 
Radionuclide Half-life (h) Energy (keV) Medical applications 
Gallium-67 
(
67
Ga) 
79.2 93, 184 and 
300 
Gallium-67 citrate; infections, 
granulomatous diseases and lymphoma 
diagnosis, temporal arteritis 
Indium-111 
(
111
I) 
67.0 171 and 245 In-111-DOTA-NAPamide; metastatic 
melanoma diagnosis 
In-111-DTPA; endocrine 
gastroenteropancreatic tumours 
Iodine-123 
(
123
I) 
13.3 159 I-123-Iomazenil; Benzodiazepine 
receptor binding, 
I-123-IMP; regional cerebral blood flow, 
I-123-β-CIT; dopamine transporter 
imaging (Parkinson's disease) 
Iodine-125 
(
125
I) 
1416 35 I-123-IACFT; dopamine transporter 
imaging 
Technetium-
99m (
99m
Tc) 
6.0 140 Tc-99m-MIBI; brain tumour diagnostics 
Tc-99m-HEXAMIBI; myocardial 
perfusion  
Tc-99m-HSA; cardiac blood pool 
imaging 
Thallium-201 
(
201
Tl) 
73 70 to 80 Tl-201; brain tumour imaging 
Tl-201; coronary artery disease 
diagnostics 
  
23 
 
3.5.1 Regulatory issues 
 
Due to the hazardous nature of ionizing radiation, the use of radioactive substances is 
guided by the radiation practices regulation. The regulation is based on the Radiation 
Act (592/91), which has been harmonized according to the basic safety standards laid 
down by the Council of the European Union in the Council Directive 96/29/Euratom. 
The nuclear safety and radiation practices regulations are issued by the Radiation and 
Nuclear Safety Authority (STUK, Finland), which belongs to the administration of the 
Ministry of Social Affairs and Health. 
 
As a general principle, three main criteria must be met before the use of radiation and 
practices involving exposure is considered acceptable (Radiation Act, 2§). First in any 
task leading to possible exposure, the benefits must be greater than the detriment 
derived from the practice. Therefore one must always respect the justification of the 
purpose of the study; hence the principle of justification. Next the practice shall be 
arranged so that the hazardous health effects from exposure are kept as low as 
reasonably possible. As a principle of optimization, it is not enough that the maximum 
allowed exposure levels are not exceeded; an investigation must be made to explore all 
available methods to reduce levels of exposure as much as possible. Lastly according to 
the principle of limitation, no single person shall exceed the maximum prescribed 
values of radiation exposure. 
 
In addition to the three principles, every instance using radiation must operate under a 
safety license (Radiation Act, 16§). License is granted by STUK when the applicant’s 
organization and facilities meet all the requirements prescribed in the Radiation Act 2§ 
and that the necessary arrangements are made in the handling of radioactive waste and 
radiation sources. 
 
Furthermore according to the Finnish Act on Animal Experimentation (62/2006) when 
animals are used for scientific purposes, all studies must be approved by the Finnish 
National Animal Experiment Board (ELLA) in addition to obtaining appropriate 
personal licenses in animal handling. The studies must also be in concordance with the 
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provisions laid down by the Animal Welfare Act (247/1996). The Ministry of 
Agriculture and Forestry is responsible for the implementation and enforcement of the 
Act’s requirements. 
 
3.5.2 Activity and exposure 
 
The energy of ionizing radiation is measured in electron volts (eV), which is the energy 
of a single electron moving across an electric potential difference of one volt; therefore 
it can be calculated that 1 eV = 1.6 x 10
-19
 J. The energy of ionizing radiation is usually 
in between 10 keV – 10 meV. 
 
The energy of radioactivity is usually related to radioactive decay. The speed of the 
decay of a radioactive material is described by the activity unit Becquerel (Bq). It 
determines the number of nuclear transitions during a period of one second; therefore 
the overall activity of radioactive material decreases over time as the number of 
radioactive atoms decrease due to nuclear transition. However the radioactive decay is 
also related to a decay constant (λ), which is characteristic to each radioisotope. 
Therefore the decay is exponential and enables the calculation of the half-life (t1/2) of 
the radioisotope and a relationship between the parameters can be found: λ = ln 2 / t1/2. 
 
Radiation exposure is measured in doses. Gray (Gy) is the unit for absorbed dose (D) 
which measures the amount of energy absorbed by a mass of one kilogram; therefore 
1 Gy = 1 J / kg. The average absorbed dose per tissue or organ (DT) can be calculated by 
dividing the amount of energy transferred from the ionizing radiation into the tissue by 
its mass: DT = D / mass of tissue. The radiation detriment can therefore be estimated 
with two computational parameters: the equivalent dose (HT) and the effective dose (E). 
The equivalent dose uses a weight coefficient (wR) which varies depending on the type 
of radiation (Table 2). The equivalent dose values can be calculated when the radiation 
exposure is evenly distributed between the tissues and organs: HT = DT x wR.  
 
The effective dose is used when a specific organ or tissue has been affected by radiation 
exposure or the exposure is unevenly distributed in the entire organism: E = HT x wT. In 
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the effective dose the weigh coefficient (wT) varies between tissue and organ types 
(Table 3). With the computational parameters, it is possible to assess the stochastic 
(probabilistic) effects of radiation exposure on the whole organism i.e. they are used to 
estimate the risks of long-term emerging detriments such as cancer or other genetic 
effects. However, ideal dosimetry is often difficult to estimate; therefore biologically 
relevant doses are studied through historical examples in hope to establish a 
standardized quantification of radiation exposure (Pass et al. 1997). 
 
The unit for equivalent and effective dose is Sievert (Sv), which is also measured in 
amount of energy per weight (1 J / kg). However the unit gray is not interchangeable 
with Sievert as it is dependent on the biological context and or radiation type indicated 
by weigh coefficients; therefore Sievert is always used in the estimation of biological 
effects of radiation exposure. 
 
 
Table 2. Weighting factors for equivalent dose calculations according to Euratom BSS 
and ICRP recommendations. 
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Table 3. Weighting factors for effective dose calculations according to Euratom BSS 
and ICRP recommendations. 
 
 
 
3.5.3 Radiation detriment 
 
The effects of radiation on tissue and cells are either somatic or genetic (UNSCEAR, 
2006). Somatic detriments affect the exposed individual and genetic effects carry over 
to the next generation and therefore are hereditary. However, radiation is used to treat 
certain conditions e.g. killing cancer cells to reduce or eliminate cancerous tissue in 
radiation therapy. 
 
Ionizing radiation causes cell death or prevents cell proliferation by damaging cellular 
DNA with inherent sensitivity to fast-replicating cells. Acute radiation syndrome (ARS) 
is a constellation of health effects caused by a loss of functionality in an organ or tissue 
when a sufficient amount of cells have died (Donelly et al. 2010). The onset of 
symptoms begins within 24 hours of exposure and may last several months (Table 4). 
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Table 4. Acute radiation syndrome symptom onset by dose of radiation exposure. Early 
symptoms are slight headaches, fatigue and weakness with mild leukopenia. Gradual 
increase of dose results in hemorrhage and infections, high fever, diarrhea, vomiting, 
nausea, shock, severe leukopenia and death. Until severe exposure of 6 gray and above 
ARS can still be treated with antibiotics, blood transfusions and stem cell transplants. At 
higher doses patients will receive mainly palliative treatment. 
 
 
 
Somatic effects can be either deterministic or stochastic (UNSCEAR, 2006). 
Deterministic effects occur only when a certain threshold has been achieved. Exceeding 
the threshold always results in immediate appearance of symptoms specific to the tissue 
exposed to ionizing radiation. The occurrence of deterministic effects increase rapidly 
after the threshold is exceeded. 
 
Stochastic effect occurrence is totally random and can be investigated only through 
statistical data (UNSCEAR, 2006). Stochastic effects are usually related to lower doses 
Neurovascular 
syndrome onset 
 
 
 
 
 
GI syndrome onset 
 
 
 
Hematopoietic 
syndrome onset 
 
≥ 12 
11 
10 
9 
8 
7 
6 
5 
4 
3 
2 
≤ 1 
Dose 
(Gy) Multiple organ 
failure, 
certain death 
Severe leukopenia, 
probable death 
LD50 with treatment 
Moderate 
leukopenia, LD50 
without treatment 
~ 100 % survival 
without treatment 
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of radiation exposure and therefore can be the result of a single normal cell mutating 
into a cancer cell. However the risks are low and it is difficult distinguish these effects 
from other sources that promote cancer. Risk assessments can still be done and an 
average risk of for example a malignant tumor growth or leukemia can be estimated. 
 
3.6 Translational aspects 
 
As imaging technologies mature, it becomes more apparent that the pre-clinical research 
protocols must have a direct translation to human applications. This requires fully 
quantitative and dynamic data gathering; therefore corrections for attenuation, scatter 
and especially partial volume averaging, as the latter is critical in imaging small 
structures of interest (Rowland & Cherry, 2008). In addition high-resolution detectors 
are necessary while still retaining an adequate sensitivity; however the main focus is 
how to translate the results from a mouse to man. 
 
The sequencing of the mouse genome in 2002 introduced a key informational tool for 
understanding the connections between mouse and man (Mouse Genome Sequencing 
Consortium, 2002). Similarities in the genomes allowed the genetic engineering of mice 
strains, which could closely simulate human diseases. However, genetically engineered 
mice are highly priced and translational studies can easily induce prohibitive costs 
(Rowland & Cherry, 2008). 
 
Ultimately small-animal imaging enables better understanding of mechanism of disease; 
in addition benefitting clinical practise. Improved disease detection, diagnosis and 
treatment response in clinical cases can be achieved with proper translation. 
 
3.6.1 Clinical SPECT/CT 
 
The clinical use of imaging units is mainly focused on oncological studies (Beyer et al. 
2000; Mariani et al. 2010). Tumour detection, progression and response to treatment can 
be investigated with molecular imaging. Several different diagnosis methods already 
exist as well as increasing applications in minimal invasive surgery (Mariani et al. 
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2010). However, applications in several non-oncological diseases are also emerging. 
Diagnosis and prognosis of patients with cardiovascular diseases with SPECT/CT has 
been adopted in many medical units. In addition cell trafficking in stem cell therapy to 
understand stem cell-host interactions would be extremely difficult without in vivo 
imaging (Zhang & Wu, 2007). 
 
The diagnostic accuracy of imaging units has ensured their usefulness in modern 
medicine, especially in tumour malignancy (Mariani et al. 2010). This has led to more 
extensive investigation of the possibilities of molecular imaging for non-invasive 
assessment of biological and biochemical processes in a living subject for clinical as 
well as in pre-clinical applications. 
 
3.6.2 Small-animal SPECT/CT 
 
Despite the connections between man and mouse genome, several challenges have to be 
addressed first to be able to understand and translate rodent data into human. Firstly the 
technical challenges; smaller objects need to be observed in great detail. Clinical 
imaging units do not have the sufficient spatial resolution to be able to gather 
satisfactory data (Rowland & Cherry, 2008). Therefore specialised units for small-
animal imaging have been developed to overcome the limitations of clinical imaging; 
non-overlapping projections obtained with multi-pinhole collimation (McElroy et al. 
2002) or coded aperture collimation where pinhole projections overlap the images onto 
the detectors (Schellingerhout et al. 2002). 
 
Other specialised apparatus is required in small-animal imaging, such as an anaesthesia 
unit. Small animals, namely rodents, are difficult and time consuming to train to lie still 
(Rowland & Cherry, 2008). In addition, acquisition times can be lengthy; therefore the 
data is acquired while the animal is anesthetized. The state of consciousness affects the 
animal physiology and therefore might affect the kinetics of administered tracers. Some 
studies have been made to investigate the differences in tracer distribution between 
conscious state and anaesthesia and statistical differences have been found in brain and 
heart uptake (Toyama et al. 2004). To address this problem; attempts to validate the 
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physiological stability has been made to establish a reliable method to compare the 
kinetic results (Sharp et al. 2005). 
 
For a small animal, the body surface area to weight ratio is much larger in comparison 
to a human, which leads to an effective heat loss. Therefore, bed warmers are necessary 
to maintain the correct body temperature while the animal is in anaesthesia (Hildebrandt 
et al. 2008). Not regulating the correct temperature might lead to different physiological 
activities that might interfere with tracer distribution. 
 
To be able to administer radiopharmaceuticals to small animals, expertise as well as 
careful planning in animal handling and study design is required (European Union 
Council Directive 86/609/EEC). The route of administration might not be available for a 
rodent that would be used in humans; therefore alternative routes have to be used. In 
addition, all working (and sample) volumes are small, which have to be taken into 
account in the study planning e.g. is the equipment sensitive enough for analysis. In 
addition, differences in animal handling can affect study results (Fueger et al. 2006). 
 
Dietary control might not be possible for small animals before acquisition. In some 
cases, food or water intake might affect the uniformity of multiple acquisitions 
(Hildebrandt et al. 2008). In addition it is unclear how the high radiation doses required 
in longitudinal studies affect these models, for example high doses could cause changes 
in tumour progression that might have an influence in the general response of the 
therapy (Rowland & Cherry, 2008). 
 
Despite all the challenges involved in the translational aspects of small-animal imaging, 
it is clear that with new emerging technologies it is possible to achieve new clinical 
applications. Numerous advancements have been made, e.g. in cardiovascular molecular 
imaging; both SPECT/CT and PET/CT already have clinical use in the diagnosis and 
detection of several cardiovascular diseases (Buxton et al. 2011). 
 
Recent subsequent breakthroughs in humanized animal models have also shown a great 
importance in studies of human cells, tissue and disease (Shultz et al 2007). Humanized 
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animal models are immunodeficient mice engrafted with human tissue, stem cells or 
peripheral-blood mononuclear cells. Therefore the study of human biological processes 
in vivo is possible without severe ethical and technical limitations. In humanized animal 
model studies, the immunodeficiency is first induced by sublethal irradiation of adult or 
newborn recipients, after which the haematopoietic system is repopulated with the use 
of self-renewing pluripotent human haematopoietic stem cells. Further advancements 
were made with the development of a complete functional human immune system, 
which provided the possibility to study both the innate and the adaptive immune 
systems in vivo (Traggiai et al. 2004). 
 
Humanized animal models are important in the study of many infectious diseases that 
do not normally infect common laboratory species, e.g. AIDS or malaria (Shultz et al. 
2007). In addition, humanized animal models can be used to study human 
autoimmunity, cancer and regenerative medicine. Especially in cancer and regenerative 
medicine, it is possible to utilize molecular imaging through immunodeficient strains 
that can be implanted with healthy or cancerous human cells without graft rejection. As 
SPECT/CT already has a firm foothold in tumour imaging (Keidar et al. 2003), in 
addition to recent studies in stem cell trafficking (Kraitchman et al. 2005). Therefore 
complementing the humanized animal studies with powerful analytical tools would 
likely to further benefit the research field in understanding human biological processes 
in cross-species environments. 
 
3.7 Imaging as a tool for biopharmaceutical research 
 
Molecular imaging has received increasing attention towards pre-clinical use, as pivotal 
trials involve considerable amount of time and significant costs (Willman et al. 2008). 
The increased investment rate of introducing novel drugs to the market subjects new 
strategies for evaluating promising drug candidates. With molecular imaging it is 
possible to observe biological activity, confirm drug targets and identify patients who 
would receive the most benefit. In addition, in vivo imaging allows the investigation of 
pharmacokinetics in an intact living organism; pharmacokinetic interactions (Guo et al. 
2009), as well as biodistribution between and within tissues (Soundararajan et al. 2009). 
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The targeting and biodistribution of intended drug candidate can be examined when an 
imaging probe interacts directly with its target (Willman et al. 2008). In this approach, 
the endogenous expression of certain proteins can be used as targets (e.g. vascular 
endothelial growth factor receptor (VEGF) in a tumour). The labelled growth factor 
(e.g. 
64
Cu-VEGF) can therefore be detected and quantified by its interaction with the 
receptor. In general, reporter genes that encode proteins that interact with imaging 
probes can be used. However, especially in the case of protein drugs, a proper delivery 
vector is required to introduce the imaging probe to into the tissue under examination. 
Therefore characterization of delivery vectors is required, e.g. siRNA delivery systems 
have already been successfully studied with molecular imaging in biopharmaceutical 
research (Merkel et al. 2009). 
 
The strength of molecular imaging in pharmacokinetic studies lies within the possibility 
to observe intact living organisms as a whole, as it is near impossible to translate in 
vitro data to fully correlate with in vivo conditions. In addition, nuclear imaging allows 
isotopic substitutions of pharmaceuticals; the physiochemical characteristics of the 
radiopharmaceutical remain the same (Willman et al. 2008); therefore the imaging 
probe has the same properties as the parent molecule. However, it is possible to change 
the characteristics of the probe without careful design (bio-isosteric substitution; 
Willman et al. 2008). 
 
Considering the conventional pre-clinical studies, with molecular imaging it is possible 
to retrieve more longitudinal data and statistical power using the same animal, also 
reducing the number of animals and cost. Furthermore the acquisition process is non-
invasive and mostly automated. However, pharmacokinetic studies are largely 
dependent on the half-life of radionuclides, as tracking efficiency is reduced when the 
radionuclide half-life is shorter than the drug half-life. In addition, metabolism and 
protein interactions have to be taken into account. It is possible that the 
radiopharmaceutical is cleaved by a metabolizing enzyme so it becomes impossible to 
distinguish between the parent molecule and the metabolite. However molecular 
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imaging combined with intermittent plasma sampling can help to counter this problem, 
but will also increase cost and time. 
 
Furthermore, it is possible to understand biological responses and therefore to assess 
treatment responses (Willman et al. 2008), e.g. dose dependency or toxicity. In addition 
molecular imaging has been used in compound screening (Kung et al. 2004). Therefore 
nuclear imaging is an attractive tool for drug development and especially in early 
pharmacokinetic studies, as many trials fail due to poor pharmacokinetic properties 
(DiMasi, 2001). Therefore, the role of molecular imaging is likely to increase in the 
near future of drug development and pharmaceutical studies. 
 
 
4 AIMS OF THE STUDY 
 
The aim of this study was to investigate the properties of plant-derived NFC as an 
injectable implant for drug release. In addition the diffusion characteristics and labelling 
properties of NFC were examined. The potential usefulness and safety of bacterial NFC 
in the medical field has already been established (Klemm et al. 2009). Furthermore only 
one study has previously suggested the use of wood pulp NFC as a potential medical 
device amongst other biomedical applications (Bhattacharya et al. 2012). However the 
differences and similarities between these materials have been comprehensively studied 
(Klemm et al. 2012), which allows the re-evaluation of the connections between the two 
nanofibrillar celluloses and further expand the possibilities of potential applications, for 
example in regards of biocompatibility and non-toxicity in biomedical sciences. 
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5 MATERIALS & METHODS 
 
5.1 Diffusion study 
 
NFC hydrogel was diluted to 1 % with ion free water. Fluorescein isothiocyanate–
dextrans of 4, 20 and 70 kDa (Sigma-Aldrich, Finland) solutions were prepared 
respectively to the concentration of 125 µg/ml. Standard cell culture multi-well dishes 
with Ø 1.12 cm
2
 well inserts were prepared for the diffusion study. In each well, 1 ml of 
ion free H2O was added into the receiver compartment before the start of the 
experiment. 300 µl of 1 % NFC was pipetted on top of the well inserts, to the apical 
side, to form an even ~2.5 mm thick layer of hydrogel. 200 µl of each dextran solution 
in a total of 3 replicates were added on top of the hydrogel and the well plates were 
placed inside the incubator to maintain a constant 37°C temperature. At each time point 
the well inserts were shifted to a new well containing 1 ml of fresh ion free H2O to 
simulate sink conditions. Well inserts were transferred to a new receiver compartment at 
15 minute intervals for 2 hours and then at 150, 180, 240, 300 and 420 minutes. After 
the experiment samples were measured in a black 96-well plate (OptiPlate, 
PerkinElmer, Finland) with a multimode well plate reader Varioskan® Flash (Thermo 
Scientific, Finland), a fluorometric measurement with excitation and emission 
wavelengths 490 nm and 520 nm respectively. Permeability coefficient values were 
calculated from the first 5 time points for each dextran (Papp = dM/dt x 1 / (A x C0), 
where Papp is the permeability coefficient, dM/dt is the efflux rate of the cumulative 
amount of study compound, A is the area of the well insert filter and C0 is the initial 
solution concentration. 
 
5.2 
99m
Tc-NFC labelling 
 
99m
Tc-NFC was prepared with slight modifications according to the procedure described 
by Schade et al. 1991 for 
99m
Tc-labelled carboxymethyl-cellulose. 
1.6 % NFC stock (GrowDex™, UPM-Kymmene, Finland) was used to prepare 1 % 
NFC hydrogel with added stannous chloride stock (17.5 µg/ml in saline solution) and 
99m
Tc-pertechnetate (
99m
TcO4
-
) stock (~ 80 MBq/ml in saline solution) to a final volume 
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of 1 ml. Briefly, 590 µl of stock NFC was added to 285 µl of stannous chloride 
dehydrate solution (Angiocis, IBA Molecular, Belgium) followed with 10 minute 
incubation and mixing. Subsequently, 125 µl of 
99m
TcO4
- 
 was added to reaction mixture 
to reach the NFC concentration of 1 % and incubated while mixing for 30 minutes. 
 
The stability of the radiolabel was investigated in neutral isotonic pH by incubating the 
1 % 
99m
Tc-NFC samples for 24 hours. Samples were prepared in stock solutions as 
described above in saline or in fetal bovine serum (FBS) (Sigma-Aldrich, Finland). 
Radiochemical purity and efficiency was tested at every time point (0, 15, 60, 120, 240 
minutes and 24 hours).  
 
Labelling efficiency and radiochemical purity of 
99m
TC-NFC was determined by TLC 
with ITLC-SG chromatography plates (Agilent Technologies, Santa Clara, CA, USA) in 
methylethylketone (MEK) solvent system. Plates were cut in smaller equally sized 
pieces and placed in standard RIA tubes for radioactive measurement with a gamma 
counter (RiaCalc. WIZ, Wallac 1480 WIZARD® 3’’, Finland). 
 
To optimize the method for 
99m
Tc-NFC labelling, various conditions were tested during 
the labelling procedure, such as buffer pH ranging from 4.74 to 8.05, different 
incubation times for 
99m
TcO4
-
/NFC reaction mixture (5, 10, 15, 20, 25 and 30 minutes) 
and stannous chloride concentrations ranging from 50 to 0.05 µg/ml. 
 
5.3 In vivo imaging 
 
This study was approved by the Finnish National Animal Experiment Board and 
performed in accordance with the Animal Welfare Act (247/1996) and Good Laboratory 
Practices for Animal Research. The release properties of plant-derived NFC implants 
were investigated with the use of radiolabelled small compounds. Implants were 
injected subcutaneously in the pelvic region and the mice were observed non-invasively 
over a 24 hour period with the use of a SPECT/CT system. After the 24 hour period the 
mice were sacrificed by cervical dislocation. 
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A total of 20 BALB/c inbred mice were obtained from a professional stockbreeder 
(Harlan Laboratories, Netherlands) and quarantined for two weeks prior to the start of 
the experiment. The mice were divided into 7 groups, A, B, C, D, E, F (n=3) and G 
(n=2). The mice in groups A and C were injected with a mixture of saline solution and 
Iodine-123-Sodium Iodine (
123
I-NaI) or a cocaine analogue Iodine-123-(2-beta-
carbomethoxy-3-beta-(4-iodophenyl)-tropane) (
123
I-β-CIT) (MAP Medical 
Technologies Oy, Finland) respectively. The mice in groups B and D were injected with 
a 5:1 mixture of 1 % NFC and 
123
I-NaI or 
123
I-β-CIT respectively (final mixture of 0.83 
% NFC hydrogel with added study compound). Group E was injected with a mixture of 
123
I-NaI and 
99m
Tc-NFC for dual-radionuclide SPECT/CT. Groups F and G were 
injected similarly with 5:1 1 % NFC and 
99m
Tc-labelled human serum albumin (HSA) 
(Sigma-Aldrich, Finland) or 
99m
Tc-labelled HSA in a saline solution respectively (final 
mixture of 0.83 % NFC hydrogel with added study compound). All mice received 50-60 
MBq/200 µl injections. 
 
99m
Tc-HSA was prepared and radiochemical purity was tested according to the 
manufacturer’s instructions (Vasculocis®, CIS bio international, France). 
Radiochemical impurities were found below the allowed 5 % of the total activity. 
  
SPECT/CT imaging was performed with a four-headed small animal scanner 
(NanoSPECT/CT, Bioscan, USA), outfitted with 1.0 mm multipinhole apertures. All 
mice were sedated with isoflurane and SPECT images were acquired 0 h (with 5 or 6 
acquisitions at 15 minute intervals), 5 h and 24 h post-injection in 16 projections using 
time per projection of 45, 90 and 180 seconds respectively. CT imaging was 
accomplished with 45 kVp tube voltage in 180 projections. For 3D co-registration and 
analysis the SPECT images were reconstructed with HiSPECT NG software (Scivis 
GmbH, Germany) and fused with CT datasets by using the molecular imaging suite 
InVivoScope™ (Bioscan Inc., USA). In the analysis, volumes of interests (VOI’s) were 
drawn at the injection site (whole NFC implant), thyroid glands, stomach, left kidney, 
heart and around the striatum depending on the study compound respectively. Counts 
within each VOI were recorded, corrected for radioactive decay and normalized to the 
activity at the time of injection. 
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6 RESULTS 
 
6.1 Diffusion study 
 
From the study compounds the 4 kDa dextran expressed the fastest diffusion rate 
through the NFC hydrogel matrix followed by the 20 and 70 kDa compounds 
respectively (Fig 5). Relatively 100 % of the smallest dextran had diffused through at 
the 420 minute time point. 68.6 % and 58.1 % of the 20 and 70 kDa dextrans 
respectively were found at the receiver compartment at the end of the experiment, 
suggesting that the size is one factor contributing to the passive diffusion rate of 
dextrans through the NFC matrix. A decrease in the diffusion was observed in the 
beginning of the experiment for 20 and 70 kDa dextrans; however the cumulative 
amount of diffused 4 kDa is nearly linear. Later during the experiment the cumulative 
amount of diffused 20 and 70 kDa dextrans is nearly linear. 
 
 
Figure 5. The diffusion of 4, 20 and 70 kDa dextrans through ~2.5 mm NFC hydrogel 
matrix. At the start of the experiment the diffusion rate of 4 kDa dextran is nearly linear 
suggesting that the NFC matrix does not hinder its movement. However the diffusion 
rate gradually decreases with the 20 and 70 kDa dextrans followed by a near linear 
diffusion later during the experiment, suggesting that the hydrogel layer is saturated first 
before the linear diffusion phase and the NFC matrix is hindering the movement of the 
larger compounds. 4 kDa dextran exhibits a slight decrease in diffusion rate at the end 
of the experiment as the amount of compound in the donor compartment is nearing 0 %. 
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The experimental Papp values for 4, 20 and 70 kDa dextrans were 8.75E-05, 6.01E-05 
and 4.49E-05 cm/sec respectively (Fig 6). The permeation coefficient is nearly linear as 
the function of dextran size is on a logarithmic scale, suggesting that the molecular 
weight and size of the compound is a clear contributor to its diffusion rate through the 
NFC matrix. Therefore the limiting factor for the passive diffusion rate of dextrans is 
more likely physical and not a chemical interaction. 
 
 
 
Figure 6. The permeability coefficient as the function of dextran size on a logarithmic 
scale. The experimental Papp values for 4, 20 and 70 kDa dextrans were 8.75E-05, 
6.01E-05 and 4.49E-05 cm/sec respectively. The dextran size shows a linear behaviour 
towards the experimental Papp values. This suggests that the size of the dextran has a 
large contribution to its diffusion rate through the NFC matrix and the rate liming factor 
is physical and not chemical. 
 
 
6.2 
99m
Tc-NFC labelling 
 
The 
99m
Tc-NFC labelling method was found highly efficient; typically resulting in over 
95 % binding rate, while less than 5 % of the technetium remained unbound (Fig 7 & 8). 
Reference samples without stannous chloride showed little binding efficiency. In 
addition NFC did not show any inherent binding affinity towards 
99m
Tc. 
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The amount of stannous chloride was investigated in the preparation of the radiolabel 
(Fig 9). It was shown that for the purpose of this experiment 5 µg/ml concentrations 
were the most optimal; however the labelling procedure was fairly insensitive towards 
the concentration changes of stannous chloride and no effect in labelling efficiency was 
found between the concentrations 50 and 0.5 µg/ml. 5 µg/ml was selected for further 
studies. 
 
 
Figure 7. The labelling efficiency of 
99m
Tc-NFC. Typically over 95 % binding was 
observed. NFC samples A and B were prepared with the aforementioned method, while 
reference samples A and B were not treated with stannous chloride. Samples that were 
not treated with stannous chloride showed poor labelling efficiency, suggesting that 
NFC does not have an inherent binding affinity towards the radiolabel in its unoxidized 
state. 
 
The changes of pH in the dilution media was investigated during the radiolabel 
preparation. It was observed that the tested pH levels did not have any noticeable effect 
on the labelling efficiency (Fig 10). Throughout the pH range of 4.74 - 8.05, the 
labelling efficiency was found well over 95 %. The saline solution pH of 7.2 was 
selected for animal studies. 
 
The incubation times before the TLC radiolabel purity confirmation were examined  
(Fig 11). From 5 to 25 minutes, the labelling efficiencies were ranging between 75.1 - 
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85.5 %. No clear cut off was found and the relative efficiencies between the incubation 
times did not show any major differences. However, it was shown that the incubation 
times less than 30 minutes were suboptimal. Therefore 30 minute incubation time was 
selected for further studies. 
 
 
 
Figure 8. Labelling of NFC with 
99m
Tc-pertechnetate. Left: with the absence of NFC the 
free 
99m
TcO4
-
 does not remain at the point of application. Right: NFC sample labelled 
with 
99m
TcO4
-
. Only a small portion of the radiolabel is shown unbound when mixed 
with NFC. 
 
The radiolabel stability was studied in a period of 24 hours in both saline and fetal 
bovine serum (FBS) samples (Fig 12). 
99m
Tc-NFC was shown to be stable during the 24 
hour period while it was incubated in FBS. However, at the 24 h time point the 
Unbound 
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Tc 
CNF labelled with 
99m
Tc 
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radiolabel functionality was lost in the saline sample (only 40.5 % labelling efficiency). 
During the first 4 hours the overall labelling efficiency remained at 81.7 and 87.2 % for 
saline and bovine serum samples respectively. 
 
 
Figure 9. The effect of the amount of stannous chloride in the radiolabel preparation. No 
major differences were found between the concentration levels of 50 - 0.5 µg/ml of 
stannous chloride. 5 µg/ml was selected for the later phases of this study. 
 
 
 
Figure 10. The effect of the pH level during radiolabel preparation. The sample dilution 
media pH levels between 4.74 and 8.05 did not show any clear effects in the final 
radiolabelling efficiency. 
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Figure 11. The effect of incubation times with stannous chloride before the 
99m
Tc-NFC 
radiolabel is ready for use. Less than 30 minute incubation is suboptimal and over 95 % 
labelling efficiencies were not observed. 
 
 
 
 
Figure 12. The stability of the 
99m
Tc-NFC radiolabel during a 24 hour period. A) The 
sample prepared in FBS remained relatively stable during the whole experiment; 
however the sample prepared in saline showed a major decrease of labelling efficiency 
at the end point of the study. B) The overall labelling efficiencies suggest that both 
samples are highly stable during the first 4 hours after sample preparation. 
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6.3 In vivo imaging 
 
 
The release and distribution of 
123
I-NaI, 
123
I-β-CIT and 99mTc-HSA was investigated 
after injecting the NFC implants imbedded with a study compound. In this preliminary 
study, compounds were selected to represent different sized molecules; two small 
molecule compounds and one large to verify the results from the diffusion study. Study 
compound and saline solution mixtures were used as controls. 
123
I-β-CIT and 123I-NaI 
were released rapidly from the NFC injections (Fig 13). 5 hours post injection both 
small compounds had been completely released from the NFC matrix. As a larger 
compound, 
99m
Tc-HSA showed a slower release times from both NFC and saline 
mixtures. Furthermore, 
99m
Tc-HSA expressed the slowest release from the NFC 
implants and 41 % of the injected dose remained within the implants 5 hours post 
injection. Fastest release profile was observed with 
123
I-NaI, as half of the dose was 
already exited the biomaterial after the first time point, while around 30 % was released 
from the 
123
I-β-CIT-NFC implants. A slightly slower release was observed with 123I-β-
CIT/NFC implants compared to the 
123
I-β-CIT/saline injections; however for the two 
smaller compounds, the differences were not apparent regardless of the study compound 
or injection medium (saline or NFC). Differences between the HSA-NFC implants and 
saline injections were observed however. In addition, a large distribution of 
99m
Tc-HSA 
was shown in the subcutaneous tissue surrounding the injection site indicating a very 
poor absorption of 
99m
Tc-HSA into the circulatory system. Slight activity was detected 
within the bloodstream (heart and left kidney); however the distinctions between the 
compound itself and its metabolites can’t be made, as it is well known that 99mTc-HSA 
does not pass the glomerular filtration under normal renal activity. 
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Figure 13. The release of 
123
I-β-CIT and 123I-NaI from NFC implants over a 5 hour 
study period (% of dose). Both compounds had been completely released from the 
implant 5 hours post injection. After the first time point, 50 % and 30 % of 
123
I-NaI and 
123
I-β-CIT had been released respectively. Faster release profile for 123I-NaI was 
observed; however no major differences were found between the saline and NFC 
biomaterial injections for both study compounds. 
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123
I-NaI was mostly distributed into the thyroid glands and stomach, in addition to being 
excreted to urine (Fig 14). Saline and biomaterial injections showed similar distribution 
profiles in the stomach (Fig 15). However a delayed accumulation into the thyroid 
glands was observed with the 
123
I-NaI-NFC injection (Fig 16). 5 hours post injection; no 
traces of study compound were found at the injection site (Fig 17). 
 
 
Figure 14. The small negatively charged 
123
I-NaI releases rapidly from the NFC matrix. 
Accumulation was observed mainly in stomach and thyroid glands. 
 
 
Figure 17. 5 hours post injection, all of 
123
I-NaI had been released from the NFC matrix. 
24 hours post injection, traces of study compound were found only from the thyroid 
glands. 
  
46 
 
 
Figure 15. 
123
I-NaI accumulation in stomach (% of dose). No differences were observed 
between the saline and NFC injections. 
 
 
Figure 16. 
123
I-NaI distribution into the thyroid glands (% of dose). A delayed 
accumulation of 
123
I-NaI was observed when the study compound was injected with the 
biomaterial. However this contradicts with the results gathered from the injection site. 
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24 hours post injection 1.85 % and 1.31 % of 
123
I-NaI dose was found in the thyroid 
glands for saline and NFC implants respectively. 
123
I-β-CIT was mostly distributed into 
the striatum (Fig 18). Distribution into specific organs in the periphery was unclear and 
no other organs were selected. During the beginning of the experiment, a slight delay in 
distribution was observed with the 
123
I-β-CIT/NFC injection compared to the saline 
injection; however the differences were not apparent (Fig 13). SPECT-CT images show 
that the study compound is more concentrated when administered with NFC, despite the 
similar release profiles (Fig 19). 
 
 
Figure 19. 
123
I-β-CIT was shown to be more concentrated at the injection site with NFC 
injections. Saline injections distributed to a wider area inside the subcutaneous tissue. 
NFC retains the study compound to a smaller area; however the differences in rate of 
release/absorption were small between the injections. 
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Figure 18. The distribution of 
123
I-β-CIT into the striatum (% of dose). A slight delay in 
distribution was observed with the 
123
I-β-CIT/NFC injections; however not apparent 
when compared to saline injections. 
 
 
The distribution rate of 
99m
Tc-HSA showed a clear difference between the NFC implant 
and saline solution (Fig 20). The release of 
99m
Tc-HSA was steady during the 24 hour 
period. However, very poor absorption was observed and 
99m
Tc-HSA distributed 
heavily in the subcutaneous tissue surrounding the injection site (Fig 21 & 22). 
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Figure 20. The release rate of 
99m
Tc-HSA from saline and NFC injections over a 5 hour 
study period (% of dose). 
99m
Tc-HSA showed a slower release profile than the smaller 
study compounds. In addition, a slower release from the NFC implants in comparison to 
the saline mixtures was observed. The release profiles for both saline and implant 
injections were steady.  
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Figure 21. 
99m
Tc-HSA release from saline (above) and NFC injections (below). NFC 
hinders the distribution of 
99m
Tc-HSA within the subcutaneous tissue. In addition 
absorption is slow from both injections, probably due to the large size of the protein, 
and low enzymatic activity within the subcutaneous tissue. 
 
Heart and the left kidney were selected to estimate the 
99m
Tc-HSA absorption into the 
cardiovascular system. No apparent accumulation to any other organ for 
99m
Tc-HSA 
was shown. No differences between the saline and implant injections were observed in 
blood pool activity, i.e. heart (Fig 23). 
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Figure 22. 5 and 24 hour images of 
99m
Tc-HSA saline (left) and CNF injections (right). 
99m
Tc-HSA is localized in around the NFC implants, and distribution in the 
subcutaneous tissue is much lower than in the saline injections. 
 
  
Figure 23. The blood pool imaging of 
99m
Tc-HSA. Heart was used to estimate 
99m
Tc-
HSA absorption over the 5 hour study period. 
99m
Tc-HSA expressed poor absorption 
from the injection site. No differences between the saline and implant injections were 
observed.  
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In addition to heart, the left kidney was observed to estimate 
99m
Tc-HSA absorption  
(Fig 24). However, 
99m
Tc-HSA should not easily pass through the glomerular filtration; 
therefore the left kidney is a better representative of its metabolites. 
 
 
Figure 24. The accumulation of technetium in the left kidney over a 5 hour study period. 
The amount observed was low for both saline and implant injections. The activity in the 
left kidney is most likely due to metabolized 
99m
Tc-HSA. 
 
The dual-tracing experiment was carried out with 
99m
Tc labelled NFC and imbedded 
with 
123
I-NaI. SPECT/CT images confirm the implant position in the pelvic region post 
injection (Fig 25 & 26); in addition the implant has remained intact during the whole 
experiment. The mice were awake and moving between the acquisitions. During this 
time the implant has not migrated nor disintegrated. Furthermore the radiolabel showed 
stability and the pertechnetate remained at the injection site within the NFC implant. 
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Figure 25. Dual-tracing experiment with pertechnetate/NFC implants imbedded with 
123
I-NaI. A, B) Mice with radiolabelled NFC. C) Mouse with unlabelled NFC. The 
implant (green) remained intact during the whole experiment. No migration or 
disintegration was observed. Mice moving between the acquisitions did not affect the 
position or the integrity of the implant. Images were taken at 5 hour time point. 
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Figure 26. The release of 
123
I-NaI from 
99m
Tc-NFC injections. Above: dual tracing 
images showing implant (red) placement and test compound release. Below: 30 minute 
image split to visualize both radiotracers separately. 
99m
Tc-NFC does not seem to 
disintegrate or absorb into the bloodstream. The NFC injections are functioning like 
drug releasing “implants”. 
 
 
7 DISCUSSION  
 
In this study, the drug release properties of a plant-derived NFC as an injectable 
biomaterial were evaluated. NFC sample was imbedded with the labelled study 
compound for SPECT/CT imaging, in addition to dual-radionuclide tracing to confirm 
biomaterial positioning. Subcutaneous administration was selected as the most 
appropriate and convenient site for implantation. 
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First, the labelling of NFC with 
99m
Tc was investigated. The results indicated that the 
labelling method showed a high binding rate with less than 5 % remaining unbound. For 
the purpose of the dual-radionuclide tracing, it is possible that the unbound technetium 
accumulates in thyroid glands; however the amount (and therefore the signal) remained 
negligible compared to 
123
I-NaI, which is generally known to accumulate heavily into 
the thyroid. Stannous chloride used for the dual-radionuclide imaging is known to have 
a low toxicity (Winship 1988). Therefore in light of current knowledge the possibility 
for human use remains viable. Due to high clearance rate of tin and the relatively low 
concentration of stannous chloride used in this study, the risks of toxic symptoms from 
tin alone is very low. In addition, stannous chloride is not required if there is no need to 
track the material itself. Furthermore the safety of nanofibrillar cellulose has been 
demonstrated by numerous studies (Pitkänen et al. 2010, Vartiainen et al. 2011), which 
is another implication for its use as biomaterial. 
 
It has been shown that NFC is highly biodurable (Märtson et al 1999). This suggests 
that the applications for a non-degrading and biocompatible material would be a long-
term drug releasing biomaterial; ideal as an extended release product for chronic 
diseases. The steady and continuous release of drug can be achieved through 
formulation processes; however further studies are required for more comparative 
analysis. 
 
The diffusion study of different molecular sized dextrans shows that the molecular 
weight and size of the compounds are contributing to the rate of passive diffusion 
through the nanofibrillar cellulose matrix. Dextrans as well as NFC are composed of 
glucose molecules and according to this study the dextrans and NFC do not show a clear 
chemical affinity, suggesting that the passive diffusion is limited by physical factors. If 
no chemical attraction is found, any smaller compounds less than 4 kDa, show a fast 
rate of diffusion basically unhindered by the NFC matrix. The movement of larger 
compounds, above 20 kDa, is hindered by nanofibrillar cellulose. Furthermore the 
release of dextrans is shown to be steady. This suggests that NFC might possess 
inherent controlled release properties for larger compounds, such as protein drugs. 
However, the possible chemical interactions between proteins and NFC should be 
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investigated individually. NFC contains many hydroxyl groups as well as some 
carboxyl groups which might interact with the drug compounds imbedded within the 
matrix; therefore making the predictions of release profiles difficult for different 
compounds. However, considering the current increase of interest in pharmaceutical 
research towards the possibilities of macromolecular protein/peptide drugs, nanofibrillar 
cellulose might offer a new potential method for nonparenteral delivery, as the 
administration of protein drugs has been one of the main challenges. 
 
The release and distribution of 
123
I-NaI and 
123
I-β-CIT (cocaine analogue) from NFC 
implants were evaluated. Both study compounds showed rapid release from the implant 
as expected regarding the diffusion study with low molecular weight compounds. 
However 
123
I-β-CIT shows a slightly slower release as a larger compound. Due to the 
rapid release, it can be determined that both compounds do not show an apparent 
binding to nanofibrillar cellulose itself. In addition, no differences were found between 
the biomaterial/study compound injections and the saline/study compound injections. 
This further indicates that the release of small compounds is not hindered by NFC. 
Rather the difference in between the release profiles of the two compounds is more 
likely explained by physiological properties than the properties of the biomaterial 
implant. 
 
The release rate of the 
99m
Tc-HSA was shown slower than the release rate of the smaller 
study compounds. In addition, a very poor absorption from the injection site into the 
circulation was observed; furthermore, 
99m
Tc-HSA distributed heavily into the 
surrounding subcutaneous tissue. The release rate of 
99m
Tc-HSA was steady during the 
whole study period; however, slower release was observed with the NFC implant 
injections than with the saline injections. This suggests that NFC as an injectable drug 
releasing biomaterial is indeed more suitable for larger compounds, such as 
macromolecular protein and peptide drugs. However, it is unclear if the drug release is 
hindered by physical factors (e.g. molecular size, molecular weight, biomaterial pore 
size) or chemical factors (e.g. chemical binding), as it has been shown that NFC can 
bind water soluble, ionizable drugs in significant quantities (Jackson et al 2011). 
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Furthermore this study focused mainly on physical and not chemical properties of the 
molecules; however NFC is known to have a slight negative surface charge (Kolakovic 
et al. 2012 B), thus it can be expected to have some repelling forces between the 
negatively charged 
123
I-NaI and 
99m
Tc-HSA. Indeed, the results indicate that the release 
of 
123
I-NaI was more rapid from the implants than from the control saline injections. 
The chemical properties are more important in smaller scale, thus the repulsion forces 
by the negative charges are greater than the physical hindrance of the NFC matrix, 
which related to molecular size, a physical factor. 
99m
Tc-HSA also has a negative 
charge; however the size of the molecule is considerably larger than 
123
I-NaI, therefore 
the physical effect of the NFC matrix in the controlled release is more dominant. 
Positively charged molecules were not investigated in this study, however considering 
the effects of the negatively charged molecules (
123
I-NaI and 
99m
Tc-HSA); it is likely 
that a more noticeable controlled release effect would be observed with positively 
charged molecules. 
 
In addition, during the study of 
99m
Tc-HSA, it was unclear how much of the 
pertechnetate would label the NFC matrix while mixing the 
99m
Tc-HSA solution with 
the biomaterial prior to injection. The labelling methods used were somewhat similar 
with both 
99m
Tc-HSA and NFC; therefore the labelling mechanism is believed to be the 
same. In the case of erroneous biomaterial labelling during the study, results would 
show as a false positive data of slower 
99m
Tc-HSA release from the biomaterial, as some 
of the NFC would be labelled instead of the 
99m
Tc-HSA. However, during the 
radiochemical purity test of the 
99m
Tc-HSA, the amount of free pertechnetate was 
observed very low (impurities were found below the allowed 5 %). Therefore, only the 
free portion of the radiolabel amongst the impurities of the total activity is theoretically 
able to form bonds with the biomaterial, which would still amount to much less than 5 
% of the whole activity. This suggests that the 
99m
Tc-HSA related data obtained in this 
study is still reliable, as the amount of possible erroneous activity detected from the 
biomaterial during the image acquisition is considerably lower. 
 
The dual-radionuclide tracing SPECT/CT images show that the NFC implant has 
remained in its site of implantation during the whole study. In addition, autopsies were 
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performed to visually inspect the implants after the 24 hour study period. Intact small 
gel-like spheroids were found at the site of injection. The mice have been awake and 
moving in between acquisitions, which indicate that the NFC implant is robust enough 
and does not migrate within the subcutaneous tissue. Furthermore the SPECT-CT 
images indicate that the NFC implant does not degrade as no technetium was observed 
outside the site of injection, which is supported by the previous studies (Märtson et al. 
1999). As a non-biodegradable material, NFC could be potentially useful as surgical 
tissue adhesive, space-filling injectable biomaterial for tissue repair, long-term drug 
delivery, and tissue engineering. However further studies are required with the use of 
plant-derived nanofibrillar cellulose as a biomedical device. Current problems might be 
concerned with the handling of the material and proper product development processes. 
 
However, most injectable biomaterials are prepared in solution, while the gelation is 
triggered by an external signal, for example phototriggering (Zhang et al. 2002) or salt- 
and pH-sensitive self-assembly (Collier & Messersmith 2004). For nanofibrillar 
cellulose, a triggering mechanism is not required, as it is readily injectable in its natural 
state. This can prove to be advantageous in the use of biomaterials as injectable 
implants, as many triggers can be either toxic or challenging to perform. The ready use 
of NFC enables simple preparations, which in addition can lower the time and costs of 
the study. However handling a gel-like material can show challenges in itself. Proper 
mixing and accurate aspirating can prove to be more difficult than when performed with 
solutions. 
 
However in the field of non-invasive and minimal invasive research, molecular imaging 
is a well suitable method for preclinical studies, which in this experiment, shows the 
potential use of NFC as a biomedical device; a drug releasing matrix. In summary, 
molecular imaging methods could be used to a great advantage in preclinical studies, as 
the data gathered related to biological processes can be done in a more meaningful 
matter in an intact living subject than compared to in vitro cell studies. However, 
considering the importance of current cell studies in the drug development process, 
molecular imaging methods should still provide invaluable supplementary data that 
could help discovering potential lead molecules, and to further evaluate their efficiency 
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and safety before clinical phases. Therefore potentially greatly reducing time and costs 
of the tedious development process, in addition to limiting the amount of failed new 
drug candidates. 
 
 
8 CONCLUSIONS 
 
This study shows a robust, simple and a reliable method of labelling NFC with 
99m
Tc, 
which could prove to be useful for any further studies involving NFC and molecular 
imaging techniques, such as SPECT/CT. The small animal imaging was carried out 
successfully; however no differences were found between the NFC and saline injections 
for the smaller compounds 
123
I-NaI and 
123
I-β-CIT. Both compounds were released 
rapidly and sustained release was not observed with the NFC injections. However with 
a larger compound, 
99m
Tc-HSA, a clear difference was found between the biomaterial 
and saline injections. The differences between the release kinetics could be explained by 
either physical or chemical interactions with NFC. Therefore, according to this study, 
the gel-like NFC could be more suitable for larger compounds, such as proteins or 
peptides, and or positively charged molecules, as NFC has a slight negative charge in 
neutral pH. The 1 % hydrogel was easily prepared and readily administered as an 
injection. In addition, the gel remained at the injection site without migrating or 
degrading, even after the subjects have been awake and moving. For larger compounds, 
NFC-hydrogel “implants” show a potential use in the biomedical field; however more 
studies are required for further discussion and conclusions. 
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